[go: up one dir, main page]

PL2158210T3 - Białka fuzyjne RAGE - Google Patents

Białka fuzyjne RAGE

Info

Publication number
PL2158210T3
PL2158210T3 PL08771049T PL08771049T PL2158210T3 PL 2158210 T3 PL2158210 T3 PL 2158210T3 PL 08771049 T PL08771049 T PL 08771049T PL 08771049 T PL08771049 T PL 08771049T PL 2158210 T3 PL2158210 T3 PL 2158210T3
Authority
PL
Poland
Prior art keywords
fusion proteins
rage fusion
rage
proteins
fusion
Prior art date
Application number
PL08771049T
Other languages
English (en)
Inventor
Gregory T Bleck
David M Hilbert
Original Assignee
Galactica Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galactica Pharmaceuticals Inc filed Critical Galactica Pharmaceuticals Inc
Publication of PL2158210T3 publication Critical patent/PL2158210T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
PL08771049T 2007-06-14 2008-06-13 Białka fuzyjne RAGE PL2158210T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94399407P 2007-06-14 2007-06-14
EP08771049.7A EP2158210B1 (en) 2007-06-14 2008-06-13 Rage fusion proteins
PCT/US2008/066956 WO2008157378A2 (en) 2007-06-14 2008-06-13 Page fusion proteins

Publications (1)

Publication Number Publication Date
PL2158210T3 true PL2158210T3 (pl) 2016-08-31

Family

ID=40156919

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08771049T PL2158210T3 (pl) 2007-06-14 2008-06-13 Białka fuzyjne RAGE

Country Status (18)

Country Link
US (3) US8398977B2 (pl)
EP (1) EP2158210B1 (pl)
JP (2) JP5706688B2 (pl)
KR (2) KR101595634B1 (pl)
CN (1) CN101842382A (pl)
AU (1) AU2008265983B2 (pl)
BR (1) BRPI0813452A2 (pl)
CA (1) CA2690056C (pl)
CO (1) CO6241158A2 (pl)
EC (1) ECSP099804A (pl)
ES (1) ES2564634T3 (pl)
IL (1) IL202443B (pl)
MX (1) MX2009013194A (pl)
NZ (1) NZ581550A (pl)
PL (1) PL2158210T3 (pl)
RU (1) RU2513695C2 (pl)
WO (1) WO2008157378A2 (pl)
ZA (1) ZA200908649B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1781700B1 (en) 2004-08-03 2014-03-19 TransTech Pharma, LLC Rage fusion proteins and methods of use
KR101580938B1 (ko) 2007-06-01 2015-12-30 유니버시티 오브 매릴랜드, 발티모어 면역글로불린 불변영역 Ｆｃ 수용체 결합제
DK2789684T3 (en) 2008-05-23 2017-02-20 Siwa Corp Methods and compositions for facilitating regeneration
EP2421892A1 (en) 2009-04-20 2012-02-29 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2011102845A1 (en) * 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
MX368531B (es) 2010-07-28 2019-10-07 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
EP3511017A1 (en) 2010-09-27 2019-07-17 Siwa Corporation Selective removal of age-modified cells for treatment of atherosclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
AU2013211824B2 (en) * 2012-01-27 2017-06-01 Gliknik Inc. Fusion proteins comprising IgG2 hinge domains
PL3016512T3 (pl) 2013-07-05 2020-09-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rozpuszczalny CD33 do leczenia zespołów mielodysplastycznych (MDS)
AU2015318036B2 (en) 2014-09-19 2021-07-01 Siwa Corporation Anti-AGE antibodies for treating inflammation and auto-immune disorders
JP6679096B2 (ja) * 2014-10-21 2020-04-15 学校法人 久留米大学 Ｒａｇｅアプタマーおよびその用途
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
ES2846024T7 (es) 2015-07-24 2023-06-22 Gliknik Inc Proteínas de fusión de fragmentos de proteína humana para crear composiciones de Fc de inmunoglobulina multimerizada de forma ordenada con unión al complemento aumentada
EP4067386A1 (en) 2016-02-19 2022-10-05 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
US11958900B2 (en) 2016-04-15 2024-04-16 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
JP2020503855A (ja) 2016-12-09 2020-02-06 グリックニック インコーポレイテッド 多量体化ストラドマーｇｌ−２０４５の製造最適化
IL266988B2 (en) 2016-12-09 2024-11-01 Gliknik Inc Methods of treating inflammatory disorders with multivalent fc compounds
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
JP6964322B2 (ja) * 2017-03-13 2021-11-10 学校法人 久留米大学 ループス腎炎を処置または予防するための医薬組成物およびループス腎炎のバイオマーカー
EP3609923A1 (en) 2017-04-13 2020-02-19 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
US10913784B2 (en) 2018-09-14 2021-02-09 BioAge Labs, Inc. RAGE fusion proteins with improved stability and ligand binding affinity and uses thereof
US11684653B2 (en) * 2019-03-06 2023-06-27 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms
CN118043351A (zh) * 2021-08-31 2024-05-14 上海医药集团股份有限公司 靶向Siglec15的抗原结合蛋白及其用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
KR100232688B1 (ko) 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
EP0672141B1 (en) 1992-10-23 2003-05-14 Immunex Corporation Methods of preparing soluble, oligomeric proteins
NO315930B1 (no) * 1995-01-18 2003-11-17 Picower Inst For Medical Res T Anvendelse av tiazoliumforbindelser ved fremstilling av farmasöytiske preparater, preparater som inneholder forbindelsene, samt nyetiazoliumforbindelser
US5656261A (en) * 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
EP1327887A3 (en) * 1995-01-18 2008-12-10 Synvista Therapeutics, Inc. Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation end products
AU1832797A (en) 1996-01-26 1997-08-20 Trustees Of Columbia University In The City Of New York, The A polypeptide from lung extract which binds amyloid-beta peptide
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
AU2696097A (en) 1996-04-16 1997-11-07 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US5819341A (en) * 1996-05-24 1998-10-13 Simantob; Constance Collapsible and convertible combination baby bed and baby carrier system
US6790442B1 (en) * 1996-06-27 2004-09-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-γ
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
WO1998040071A1 (en) 1997-03-11 1998-09-17 The General Hospital Corporation Identification of agents for use in the treatment of alzheimer's disease
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
US6380165B1 (en) * 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6465422B1 (en) 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
US6706683B1 (en) * 1998-09-29 2004-03-16 Asahi Kasei Pharma Corporation Method for controlling the release of granules
US6753150B2 (en) 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
HK1041293B (en) * 1998-10-06 2008-01-25 The Trustees Of Columbia University In The City Of New York Extracellular novel rage binding protein (en-rage) and uses thereof
US6605642B2 (en) * 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
US6787566B2 (en) * 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
US6589944B1 (en) 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
FR2797402B1 (fr) * 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
EP1307219A4 (en) 1999-08-13 2005-04-06 Univ Columbia METHODS OF INHIBITING BETA FIBRILLE BINDING BETA TO RAGE RECEPTOR, AND CONSEQUENCES THEREOF
WO2001018060A1 (fr) 1999-09-08 2001-03-15 Toray Industries, Inc. Materiaux de circulation extracorporelle, adsorbants de facteurs de complication diabetique, reservoirs servant a eliminer des facteurs de complication diabetique et procede d'elimination de facteurs de complication diabetique
EP1287162A2 (en) 1999-10-21 2003-03-05 Case Western Reserve University Gene expression profiling of inflammatory bowel disease
CA2382165A1 (en) * 1999-12-08 2001-06-14 Genset S.A. Full-length human cdnas encoding potentially secreted proteins
AU4721901A (en) 2000-02-25 2001-09-03 Immunex Corp Integrin antagonists
DE60129008T2 (de) * 2000-04-14 2007-10-11 Niadyne Corp., Tucson Methode zur identifizierung von regulatoren der bildung von protein-age-derivaten
AU2001255436A1 (en) 2000-04-17 2001-10-30 Transtech Pharma Protein expression system arrays and use in biological screening
US7140063B2 (en) 2000-05-05 2006-11-28 Osborne James J Multi-use and decorative bathing implement
US20020037538A1 (en) 2000-05-09 2002-03-28 Trepicchio William L. Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US6908741B1 (en) 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US20020052475A1 (en) 2000-07-20 2002-05-02 Schering Ag High affinity soluble interleukin-18 receptor
ATE342980T1 (de) 2000-08-08 2006-11-15 Zymogenetics Inc Lösliche zcyctor 11 cytokinrezeptoren
US6825164B1 (en) * 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
EA200300442A1 (ru) * 2000-10-02 2003-10-30 Редди Ю Эс Терапьютикс, Инк. Способы и композиции для лечения воспалительных заболеваний
CA2424668A1 (en) 2000-10-06 2002-04-11 Novartis Ag Targeting molecules for adenoviral vectors
AU2002213192A1 (en) 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
PL366250A1 (pl) 2000-12-29 2005-01-24 Reddy Us Therapeutics, Inc. Sposoby i kompozycje do wykrywania związków modulujących odpowiedzi zapalne
DE10109466B4 (de) 2001-02-28 2008-01-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und Mittel zur Modifikation humaner Angiogenese
JP3837494B2 (ja) * 2001-03-19 2006-10-25 国立大学法人金沢大学 可溶型ｒａｇｅタンパク質
JP2006512900A (ja) * 2002-08-16 2006-04-20 ワイス Ｒａｇｅ関連疾患の治療用組成物及び方法
EP1771565B1 (en) 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Rage protein derivatives
EP1781700B1 (en) * 2004-08-03 2014-03-19 TransTech Pharma, LLC Rage fusion proteins and methods of use
US20060078562A1 (en) * 2004-08-03 2006-04-13 Mjalli Adnan M RAGE fusion proteins and methods of use
CA2581505A1 (en) * 2004-09-27 2006-04-06 Centocor, Inc. Srage mimetibody, compositions, methods and uses
CA2631240A1 (en) * 2004-12-03 2006-06-08 Xoma Technology Ltd. Methods and materials for expression of a recombinant protein
US20080207499A1 (en) * 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
EP1909834A2 (en) 2005-07-18 2008-04-16 Critical Therapeutics, Inc. Use of hmgb1 antagonists for the treatment of inflammatory skin conditions
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
WO2007130302A2 (en) 2006-05-05 2007-11-15 Transtech Pharma, Inc. Rage fusion proteins, formulations, and methods of use thereof
MX380352B (es) 2006-06-12 2025-03-12 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
WO2008100470A2 (en) 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
WO2008137552A2 (en) 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
WO2008153957A1 (en) 2007-06-07 2008-12-18 The Trustees Of Columbia University In The City Of New York Uses of rage antagonists for treating obesity and related diseases

Also Published As

Publication number Publication date
US20100291081A1 (en) 2010-11-18
JP5887441B2 (ja) 2016-03-16
ZA200908649B (en) 2010-08-25
KR20100025574A (ko) 2010-03-09
CA2690056A1 (en) 2008-12-24
AU2008265983A1 (en) 2008-12-24
CO6241158A2 (es) 2011-01-20
EP2158210A4 (en) 2010-06-30
WO2008157378A3 (en) 2009-02-26
US20130177560A1 (en) 2013-07-11
EP2158210A2 (en) 2010-03-03
US20150368315A1 (en) 2015-12-24
KR101595634B1 (ko) 2016-02-18
JP2010529860A (ja) 2010-09-02
RU2010100913A (ru) 2011-07-20
EP2158210B1 (en) 2015-12-09
RU2513695C2 (ru) 2014-04-20
KR20130059461A (ko) 2013-06-05
JP5706688B2 (ja) 2015-04-22
CA2690056C (en) 2017-08-29
US9399668B2 (en) 2016-07-26
CN101842382A (zh) 2010-09-22
ECSP099804A (es) 2010-03-31
IL202443B (en) 2018-05-31
AU2008265983B2 (en) 2013-06-20
US9066927B2 (en) 2015-06-30
ES2564634T3 (es) 2016-03-28
IL202443A0 (en) 2011-08-01
BRPI0813452A2 (pt) 2017-05-23
WO2008157378A2 (en) 2008-12-24
WO2008157378A8 (en) 2010-01-14
US8398977B2 (en) 2013-03-19
JP2015146809A (ja) 2015-08-20
MX2009013194A (es) 2010-03-30
KR101361355B1 (ko) 2014-02-12
NZ581550A (en) 2012-01-12

Similar Documents

Publication Publication Date Title
ZA200908649B (en) Rage fusion proteins
IL275846A (en) ACTRIIB–FC truncated fusion proteins
IL196889A0 (en) Albumin-insulin fusion proteins
IL204839A0 (en) Albumin fusion proteins
IL202128A0 (en) Immunoglobulin fusion proteins
SI3118220T1 (sl) Protein
ZA200901280B (en) Exendin fusion proteins
EP2173170A4 (en) ANNEXED HETEROCYCLES
IL205716A0 (en) Formulations for taci-immunoglobulin fusion proteins
LT2144924T (lt) Sulieto baltymo vakcina
EP1934372A4 (en) SSB-POLYMERASE HYBRID PROTEINS
GB0611116D0 (en) Proteins
IL196014A0 (en) FUSED [d]PYRIDAZIN-7-ONES
ES2569360T8 (es) Proteínas de fusión de ácaros
GB0719231D0 (en) Protein
GB0601976D0 (en) Proteins
GB0725201D0 (en) Peptide fusion proteins
GB0620735D0 (en) Proteins
IL206334A0 (en) Sarp-i fusion proteins and their use
GB0700759D0 (en) Novel fusion protein
GB0720563D0 (en) Protein
GB0713169D0 (en) Fusion proteins
GB0709707D0 (en) Novel fusion protein
GB0612623D0 (en) Proteins
GB0614682D0 (en) Proteins